Insitro
Founded Year
2018Stage
Series C | AliveTotal Raised
$643MLast Raised
$400M | 5 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-118 points in the past 30 days
About Insitro
Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.
Loading...
Insitro's Products & Differentiators
Statistical genetics
ML-enabled statistical genetics to discover targets and patient segments
Loading...
Research containing Insitro
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Insitro in 4 CB Insights research briefs, most recently on Aug 22, 2025.
Aug 22, 2025 report
Book of Scouting Reports: Generative AI in Healthcare & Life Sciences
Expert Collections containing Insitro
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Insitro is included in 7 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,309 items
AI 100 (All Winners 2018-2025)
200 items
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Artificial Intelligence (AI)
20,894 items
Insitro Patents
Insitro has filed 26 patents.
The 3 most popular patent topics include:
- biotechnology
- molecular biology
- transcription factors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/24/2024 | 3/25/2025 | Genetics, Biological databases, Bioinformatics, Rare diseases, Molecular biology | Grant |
Application Date | 4/24/2024 |
|---|---|
Grant Date | 3/25/2025 |
Title | |
Related Topics | Genetics, Biological databases, Bioinformatics, Rare diseases, Molecular biology |
Status | Grant |
Latest Insitro News
Nov 13, 2025
News provided by Share this article Robotics, Waabi, and Zoox take the stage at the signature annual AI event business of intelligence Joseph Gordon-Levitt, Actor, Filmmaker, Entrepreneur, explores AI's impact on creativity Hollywood NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Fortune announced today the addition of several speakers for its fifth annual Fortune Brainstorm AI, December 8-9 at the St. Regis in San Francisco. Fortune Brainstorm AI will convene the technologists, entrepreneurs, Fortune Global 500 executives, investors, policymakers, and the brilliant minds in between to explore and interrogate the most pressing questions about AI at another pivotal moment. This year, Fortune will explore how AI agents are driving productivity, how businesses are moving from planning to implementation, and how policy shifts are shaping that progress. Over two days, executives will discuss the latest AI advancements, real-world deployments, and strategies for sustainably and responsibly managing AI's growing resource demands. The event kicks off with a mainstage session featuring actor, filmmaker, and entrepreneur Joseph Gordon-Levitt, who explores how AI is transforming creativity and authorship. Drawing from his experience with HITRECORD and his new Netflix thriller, he offers a candid look at the future of art and human originality in the age of machine intelligence. Throughout Day 1, attendees will hear from leading voices in AI, including Justin Boitano, VP, Enterprise AI Products, NVIDIA; Thomas Kurian, Chief Executive Officer, Google Cloud; Rene Haas, Chief Executive Officer, Arm; and Sasan Goodarzi, Chief Executive Officer, Intuit. The day will conclude with an engaging session exploring how AI is reshaping Hollywood and why the future of art must remain collaborative and human, featuring Natasha Lyonne, Cofounder, Asteria Film Co. Day 2 will open with Brad Lightcap, Chief Operating Officer at OpenAI, discussing how the company is scaling responsibly, sustaining innovation at breakneck speed, and balancing ambition with accountability in the race to commercialize intelligence. The program will continue with mainstage sessions with Michael Intrator, Cofounder and CEO, CoreWeave, and Ali Ghodsi, Chief Executive Officer, Databricks. Additional speakers include: MJ Burk Chun, VP of Product & Design and Cofounder, Serve Robotics David Ko, Chief Executive Officer, Calm Daphne Koller, CEO and Founder, insitro Jesse Levinson, Cofounder and CTO, Zoox Allie K. Miller, Chief Executive Officer, Open Machine; Fortune 500 AI Advisor Panos Panay, Senior Vice President, Devices and Services, Amazon Iddris Sandu, Founder, OpenMatter Raquel Urtasun, Founder and CEO, Waabi Stephanie Zhan, Partner, Sequoia Capital For more information, including the full agenda and speakers' list, visit the event website here . Brainstorm editorial director Andrew Nusca and co-chairs Jason Del Rey, Allie Garfinkle, and Jeremy Kahn will lead the Brainstorm AI event. The 2025 Fortune Brainstorm AI in San Francisco is presented in collaboration with Founding Partner Accenture, Premier Partner Rubrik, and Partners Blackbaud, IDA Ireland, and Workday. About Fortune: Fortune is a global multi-platform media company built on a legacy of trusted, award-winning reporting and information for those who want to make business better. Independently owned, Fortune tells the stories of the world's biggest companies and their leaders as well as a new generation of innovators who are moving business forward. Digitally and in print, Fortune measures corporate performance through rigorous benchmarks, and holds companies accountable, in regions around the world. Its iconic rankings include Fortune 500, Fortune Global 500 , Most Powerful Women , and World's Most Admired Companies . Fortune builds world-class communities by convening industry thought leaders for exclusive summits and conferences, including the Fortune Global Forum , Brainstorm Tech , and Fortune Most Powerful Women . For more information, visit fortune.com . Media Contacts:
Insitro Frequently Asked Questions (FAQ)
When was Insitro founded?
Insitro was founded in 2018.
Where is Insitro's headquarters?
Insitro's headquarters is located at 279 East Grand Avenue, South San Francisco.
What is Insitro's latest funding round?
Insitro's latest funding round is Series C.
How much did Insitro raise?
Insitro raised a total of $643M.
Who are the investors of Insitro?
Investors of Insitro include ARCH Venture Partners, Foresite Capital, Andreessen Horowitz, Two Sigma Ventures, Third Rock Ventures and 19 more.
Who are Insitro's competitors?
Competitors of Insitro include BioSymetrics, Valo Health, Healx, Isomorphic Laboratories, Atomwise and 7 more.
What products does Insitro offer?
Insitro's products include Statistical genetics and 2 more.
Loading...
Compare Insitro to Competitors
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
Isomorphic Laboratories serves as a digital biology company operating in the pharmaceutical and artificial intelligence sectors. The company's main service is to use artificial intelligence, specifically machine learning, to transform and expedite the drug discovery process. The company primarily serves the pharmaceutical industry. It was founded in 2021 and is based in London, United Kingdom.
Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Healx focused on drug discovery in the healthcare sector. The company specializes in developing treatments for rare diseases by leveraging artificial intelligence and drug development expertise. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.
Standigm specializes in AI-driven drug discovery within the pharmaceutical industry. The company provides services, including target identification, lead generation, and optimization, as well as AI SaaS solutions for drug development. Standigm primarily serves sectors engaged in pharmaceutical research and drug development. It was founded in 2015 and is based in Seoul, South Korea.
Loading...